GenNext Announces Scientific Contributions to this Year’s California Separation Science Society Meeting
From the keynote address to luncheon presentations and posters, CASSS MS delegates will be exposed to the latest advancements in technology for modern Higher Order Structural analysis.
Half Moon Bay, CA – September 5, 2023 – GenNext Technologies, Inc., provider of novel instrumentation, software, and services for structural biology research announced its scientific offerings to the 2023 California Separation Science Society combined Mass Spectrometry and Higher Order Structure (CASSS MS/HOS) meetings.
Delegates will learn about “Hacking Structural Biology for Drug Delivery Using Protein Footprinting Based Mass Spectrometry” during the Keynote Presentation by Mark Chance of Case Western Reserve University. Mark will disucss how the opportunities have never been greater for the application of MS to provide higher order structure (HOS) and dynamics information to drive small molecule and biologics-based drug programs. This lecture will illustrate novel Protein Footprinting-MS approaches integrated with computation, cryo-EM and or crystallography data to advance a range of state-of-the-art industry drug programs.
In the Emerging Mass Spectrometry Technologies for HOS section, Dr. Lisa Jones from the University of California, San Diego will review “Protein Footprinting for Structural Biology in Complex Model Systems.” Dr. Jones will describe how protein footprinting identified protein-protein interaction sites and regions of conformational change through modification of solvent accessible sites in proteins. The Jones team has further extended footprinting to study proteins in their native cellular environment, especially useful for the study of membrane proteins and proteome-wide structural biology. The Jones lab identified on and off targets of the anti-cancer drug methotrexate in leukemia cells to distinguish downstream structural changes that occur due to drug treatment. Additionally, she will describe her analysis of C. elegans, enabling the study protein structure directly in an animal model for human disease.
During the Technical Seminar on “Monoclonal Antibody Therapeutic Characterization using Flash Oxidation (Fox®) Protein Footprinting Technology,” Dr. Emily Chea of GenNext will detail how the Fox System can investigate the effects of epitope/paratope mapping, aggregation-interface identification, formulation, small molecule binding, and other factors, thereby enhancing the understanding and significance of therapeutic HOS. This presentation will provide background on the Fox System, how it is being applied to characterize biotherapeutic HOS, and the forthcoming advancements to the Fox System innovation.
Finally, two Posters will be on display on “Improving TNFα’s Epitope Identification with Residue Level Hydroxyl Radical Protein Footprinting using the Sciex ZenoTOF 7600” and “Characterizing Glycan-Induced Structural Changes and Binding Interfaces for IgG1-C1q Complex using Hydroxyl Radical Protein Footprinting.”
“The CASSS MS meeting is a major focus of the GenNext team every year,” stated Scot Weinberger, CEO of GenNext Technologies. “We are committed to educating the structural biology community on the advancements to science that are made possible with our Fox Protein Footprinting technology. We are proud to be making such a rich scientific contribution to this year’s conference.”
About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.
Scot R. Weinberger
Founder and CEO